Company intelligence / Profile preview
Cytokine PharmaSciences, Inc.
King of Prussia, Pennsylvania, United Statesferring.com ↗
- Ownership
- Private
- Employees
- ~70
- Development stage
- Other
01
Overview
The company had multiple products in clinical development, including CPSI-2364, an orally active small-molecule inhibitor of TNF-alpha and other pro-inflammatory cytokines. A Phase I study of CPSI-2364 was completed with positive safety results. The company also had Imalumab in Phase 2 for Lupus Nephritis.
- Therapeutic areas
- OncologyImmunologyDermatologyGastroenterologyInfectious Diseases
- Modalities
- Small moleculesMonoclonal antibodyControlled-release drug delivery products
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Cytokine PharmaSciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytokine PharmaSciences, Inc..